This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: March 31st, 2010 - March 31st, 2011
This activity was developed for oncology nurses and pharmacists who wish to enhance their competence concerning the treatment of patients with chemotherapy-induced nausea and vomiting.
At the completion of this activity participants should be able to:
- Discuss recent advances and emerging trends in the treatment of patients with chemotherapy-induced nausea and vomiting (CINV)
- Review best practices for the management and supportive care of patients with CINV, with emphasis on evidence-based practice guidelines
- Examine effective treatment strategies for improving outcomes in patients with CINV
- Describe the impact of poorly controlled CINV, including potential complications and associated burden and cost
Agenda -1 hour
• Articles/Commentaries: 45 minutes
• Evaluation/Post-Test: 15 minutes
Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.0 contact hour.
Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal program number for this activity is 0468-9999-10-009-H01-P.
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakerâ€™s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.
The associates of Medical Learning Institute, Inc., and Center of Excellence Media, LLC, have no financial relationships to disclose.
Peer reviewer - Jayshree Shah, RN, APN-C, MSN, BSN, BS, is on the speaker's bureau for Bristol-Myers Squibb, Celgene,Merck, and Novartis, and is on the advisory board for Bristol-Myers Squibb and Novartis.
Steven M. Grunberg, MD, is on the advisory board for Genentech, is a consultant to GlaxoSmithKline, Helsinn Healthcare SA, Merck, and Shin Nippon Biomedical Laboratories, Ltd, has received honoraria from Helsinn Healthcare SA and Merck, and has stock in Merck.
*Lisa Lohr, PharmD, BCPS, BCOP, has nothing to disclose.
Jennifer Webster, MN, RN, AOCN, is on the speaker's bureau for Amgen and Eisai, and is on the advisory board for Eisai and Merck.
*Content will include non-FDA-approved uses.
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.